Ondansetrón Bluefish (Ondansetron)

Ondansetron, the active ingredient in Ondansetrón Bluefish, is a serotonin 5‑HT3 receptor antagonist presented as a tablet for oral use. It is used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetrón Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is employed across several clinical pathways that involve emesis control. - Chemotherapy‑induced nausea and vomiting (CINV): Reduces the frequency and severity of nausea and vomiting associated with cancer chemotherapy. - Radiation‑induced nausea and vomiting (RINV): Helps control nausea and vomiting that occur during or after radiation treatment. - Post‑operative nausea and vomiting (PONV): Prevents nausea and vomiting following surgical procedures. - Hyperemesis gravidarum (severe pregnancy‑related nausea): Provides symptom relief when other treatments are insufficient.

Side effects are generally mild but can vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported by many patients. - Constipation: reduced bowel movements or hard stools. - Diarrhoea: occasional loose stools. - Fatigue: feeling unusually tired. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation that may lead to irregular heart rhythm. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic drugs. - Hepatic dysfunction: abnormal liver enzyme elevations. - Vision changes: blurred vision or visual disturbances.

When using Ondansetrón Bluefish, consider the following safety measures: - Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be monitored. - Drug interactions: review concomitant medications for serotonergic activity. - Pregnancy: use only if the potential benefit outweighs risk; discuss with a healthcare professional. - Breastfeeding: assess risk versus benefit before use. - Renal/hepatic impairment: dose adjustment may be required; follow prescriber guidance. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Apomorphine: may cause severe hypotension and loss of consciousness. - Certain anti‑arrhythmic drugs (e.g., quinidine, amiodarone): increase risk of QT prolongation. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): elevate risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug exposure. - Oral contraceptives: potential reduction in contraceptive effectiveness.